Elan Ezickson joined our Board in July 2019. He brings extensive biopharmaceutical, operational, strategic, and capital formation expertise to the Carmine Therapeutics board. He most recently served as the Chief Operating Officer and head of corporate development at Scholar Rock Holding Corporation, a clinical stage biotechnology company focused on novel oncology and rare disease treatments. At Scholar Rock, Mr. Ezickson directed corporate development, operations and strategy, and played a significant role in corporate finance, leading the company's initial public offering.
Prior to joining Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals where he built and oversaw corporate development, commercial operations, technical operations, medical affairs, program management, and legal functions and led capital raising and licensing efforts with multinational pharmaceutical companies. Prior to Aveo, he was at Biogen in roles that included President of Biogen Canada, Program Executive, and Associate General Counsel.
Mr. Ezickson currently serves on the Boards of Directors of three clinical stage biotechnology firms including Marinus Pharmaceuticals, Tvardi Therapeutics, and Ziopharm Oncology. He holds a Bachelor of Arts degree in political science from Yale University and a Juris Doctorate from the Columbia University School of Law.